Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant had given written informed consent.~* Young adult participants \>=18 to \<=30 years old at Screening, with a confirmed diagnosis of T1DM made at least 1 year prior to informed consent.~* Participants were being treated with insulin or insulin analogue delivered via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).~* At Screening, must had A1C \>= 9.0%.~* Must be willing and able to perform self-monitored blood glucose (SMBG) and complete the study diary.~* Females of childbearing potential must use an adequate method of contraception and had a negative pregnancy test.~Exclusion Criteria:~* Any prior use of LX4211/sotagliflozin.~* Use of antidiabetic agent other than insulin or insulin analogue at the time of screening.~* Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to start of the placebo Run-in Period.~* Chronic systemic corticosteroid use.~* Type 2 diabetes, or severely uncontrolled diabetes mellitus as determined by the Investigator.~* History of diabetic ketoacidosis (DKA) or nonketotic hyperosmolar state within 6 months prior to the Screening Visit.~* History of severe hypoglycemic event within 1 month prior to the Screening Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 12 weeks.
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before the first meal of the day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).